Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
NVCR
NVCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NVCR News
Novocure to Participate in Global Healthcare Conference
Feb 27 2026
Businesswire
Novocure to Participate in Global Healthcare Conference
Feb 27 2026
Newsfilter
NovoCure Reports Record Revenue and Growth in 2025 Earnings Call
Feb 26 2026
seekingalpha
NovoCure Q4 Earnings Beat Expectations with Positive Guidance
Feb 26 2026
seekingalpha
NovoCure Q4 Earnings Announcement Scheduled
Feb 25 2026
seekingalpha
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
Feb 17 2026
PRnewswire
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
Feb 17 2026
PRnewswire
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
Feb 17 2026
Newsfilter
Soleus Capital Increases Stake in Celcuity
Feb 13 2026
Fool
Novocure Price Target Raised to $47 Following FDA Approval
Feb 12 2026
stocktwits
U.S. Stocks Decline Midway, Nasdaq Drops Over 350 Points
Feb 12 2026
Benzinga
NovoCure Shares Surge Following FDA Approval of Optune Pax
Feb 12 2026
Benzinga
HubSpot Reports Strong Q3 Earnings, Shares Surge 9.4%
Feb 12 2026
Benzinga
U.S. Stock Futures Rise as Market Sentiment Improves
Feb 12 2026
Benzinga
Biotech Stock Soars 25% Following FDA Approval News
Feb 12 2026
Barron's
Novocure's Optune Pax FDA Approval Boosts Shares by 23%
Feb 12 2026
seekingalpha
Show More News
